首页> 外文期刊>Antimicrobial agents and chemotherapy. >Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States
【24h】

Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States

机译:饮食和禁食状态下健康受试者口服SUBA-伊曲康唑和Sporanox胶囊制剂的伊曲康唑和羟基曲康唑的群体药代动力学模型

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Itraconazole is an orally active antifungal agent that has complex and highly variable absorption kinetics that is highly affected by food. This study aimed to develop a population pharmacokinetic model for itraconazole and the active metabolite hydroxyitraconazole, in particular, quantifying the effects of food and formulation on oral absorption. Plasma pharmacokinetic data were collected from seven phase I crossover trials comparing the SUBA-itraconazole and Sporanox formulations of itraconazole. First, a model of single-dose itraconazole data was developed, which was then extended to the multidose data. Covariate effects on itraconazole were then examined before extending the model to describe hydroxyitraconazole. The final itraconazole model was a 2-compartment model with oral absorption described by 4-transit compartments. Multidose kinetics was described by total effective daily dose-and time-dependent changes in clearance and bioavailability. Hydroxyitraconazole was best described by a 1-compartment model with mixed first-order and Michaelis-Menten elimination for the single-dose data and a time-dependent clearance for the multidose data. The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects. Food resulted in a 27% reduction in bioavailability and 58% reduction in the transit absorption rate constant compared to that with the fasted state, irrespective of the formulation. This analysis presents the most extensive population pharmacokinetic model of itraconazole and hydroxyitraconazole in the literature performed in healthy subjects. The presented model can be used for simulating food effects on itraconazole exposure and for performing prestudy power analysis and sample size estimation, which are important aspects of clinical trial design of bioequivalence studies.
机译:伊曲康唑是一种口服活性抗真菌剂,具有复杂且高度可变的吸收动力学,受食物的影响很大。这项研究旨在建立伊曲康唑和活性代谢物羟基伊曲康唑的群体药代动力学模型,尤其是量化食品和制剂对口服吸收的影响。血浆药代动力学数据收集自七个I期交叉试验,比较了伊曲康唑的SUBA-伊曲康唑和Sporanox制剂。首先,开发了单剂量伊曲康唑数据模型,然后将其扩展到多剂量数据。然后在扩展模型以描述羟基依他康唑之前,先检查对伊曲康唑的协变量影响。最终的伊曲康唑模型是2室模型,口服吸收由4个转运室描述。多剂量动力学通过清除和生物利用度的总有效日剂量和时间依赖性变化来描述。用单室混合一阶模型和Michaelis-Menten消除法对单剂量数据和多剂量数据随时间的清除率最好地描述了羟基异康唑。与Sporanox相比,SUBA-伊曲康唑的相对生物利用度为173%,受试者之间的相对生物利用度降低了21%。与禁食状态相比,食品与禁食状态相比,生物利用度降低了27%,运输吸收常数常数降低了58%。该分析提供了在健康受试者中进行的文献中伊曲康唑和羟基伊曲康唑最广泛的群体药代动力学模型。提出的模型可用于模拟食物对伊曲康唑暴露的影响以及进行研究前能力分析和样本量估计,这是生物等效性研究临床试验设计的重要方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号